Tengion, Inc. operates as a regenerative medicine company. The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials that are implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Its product portfolio includes Neo-Kidne...
Tengion reported revenue of $0 for fiscal year 2013, and net income of -$18.93 million. In Q3 2014 (the quarter ended September 30, 2014) revenue was $0.
Figures from company filings; latest fiscal year ended December 31, 2013.
From state WARN notices, SEC filings and news reports. Reported: news reports only. Confirmed: an official filing exists.
Tengion had 0 layoffs in the last 12 months, and 1 in all (the earliest dated December 5, 2014).
Layoffs, 12 months
0
Workers not stated
Layoffs in all
1
Earliest dated Dec 5, 2014
Workers in all
-
Where the sources state it
Newest layoff
Dec 5, 2014
Announced date
| Date | Place | Workers | Status | Sources |
|---|---|---|---|---|
| Dec 5, 2014 | United States | not stated | Confirmed | SEC 8-K |
No profile data available.